

IL12B

Research Grade Briakinumab

Catalog No.	DHD84002A	Quantity:	100 µg
	DHD84002B		1.0 mg

Alternate Names: Interleukin-12 subunit beta, Il-12 subunit p40, NK cell stimulatory factor chain 2, NKSF2, Cytotoxic lymphocyte maturation factor 40 kDa subunit, CLMF p40, ABT-874, J695

Description: Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. This the antibody targets the interleukins 12 and 23.

Concentration: 1.0 mg/ml, lot specific

UniProt ID (target): P29460

Source: XtenCHO cell line

Isotype: Human IgG1 lambda

INN: Briakinumab

Specificity: Human IL-12 subunit p40

Endotoxin: ≤ 0.01 EU/µg by LAL analysis

Formulation: 0.01M PBS, pH 7.4

Purification: Protein A/G affinity chromatography

Purity: > 95% as determined by SDS-PAGE

Storage & Stability: Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. **Avoid freeze/thaw cycles.**

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

